Category I
Category II (Specific tumors)
Please select "Category II (Specific tumors)" for abstracts that fall under clinical trials or case reports/series (including cross-organ treatments).
Category I
1.Chemical carcinogenesis/Radiation carcinogenesis
| Ⅰ-1-1 |
Carcinogens and their risk assessment |
| Ⅰ-1-2 |
DNA damage and carcinogenesis |
| Ⅰ-1-3 |
Oxidative stress |
| Ⅰ-1-4 |
Others |
2.Experimental animal models/ Genetically-engineered animals
| Ⅰ-2-1 |
Gene-manipulated animal models |
| Ⅰ-2-2 |
Animal models for carcinogenesis |
| Ⅰ-2-3 |
Patient-derived experimental model |
| Ⅰ-2-4 |
Others |
3.Virus/Infection/Inflammation
| Ⅰ-3-1 |
Viral infection and cancer |
| Ⅰ-3-2 |
Bacteria/Microbiome and cancer |
| Ⅰ-3-3 |
Inflammation and cancer |
| Ⅰ-3-4 |
Others |
4.Oncogenes/Tumor-suppressor genes
| Ⅰ-4-1 |
Ras and related genes |
| Ⅰ-4-2 |
p53 and related genes |
| Ⅰ-4-3 |
Rb/p16 and related genes |
| Ⅰ-4-4 |
Wnt signaling-related genes |
| Ⅰ-4-5 |
Other oncogenes/Tumor-suppressor genes |
| Ⅰ-4-6 |
Others |
5.Signal transduction and gene expression
| Ⅰ-5-1 |
Intracellular signal transduction |
| Ⅰ-5-2 |
Extracellular/Intercellular signaling factors |
| Ⅰ-5-3 |
Regulation of gene expression |
| Ⅰ-5-4 |
Non-coding RNAs |
| Ⅰ-5-5 |
Others |
6.DNA replication/Cell cycle/Genomic instability
| Ⅰ-6-1 |
Cell cycle/Checkpoint |
| Ⅰ-6-2 |
DNA replication |
| Ⅰ-6-3 |
DNA repair |
| Ⅰ-6-4 |
Genomic instabilityy |
| Ⅰ-6-5 |
Others |
7.Cancer genome/Genetics
| Ⅰ-7-1 |
Genomic analysis |
| Ⅰ-7-2 |
Clonal evolution |
| Ⅰ-7-3 |
Chromosomal translocation/Gene rearrangement |
| Ⅰ-7-4 |
Genomic medicine/Precision medicine |
| Ⅰ-7-5 |
Others |
8.Epigenetics
| Ⅰ-8-1 |
DNA methylation |
| Ⅰ-8-2 |
Histone modification |
| Ⅰ-8-3 |
Chromatin structure |
| Ⅰ-8-4 |
Others |
9.Invasion/Metastasis
| Ⅰ-9-1 |
Cell adhesion/Invasion |
| Ⅰ-9-2 |
Extracellular matrices |
| Ⅰ-9-3 |
EMT (epithelial-mesenchymal transition) |
| Ⅰ-9-4 |
Circulating tumor cells |
| Ⅰ-9-5 |
Angiogenesis |
| Ⅰ-9-6 |
Metastasis models |
| Ⅰ-9-7 |
Others |
10.Characteristics of cancer cells and host cells
| Ⅰ-10-1 |
Cancer stem cells |
| Ⅰ-10-2 |
Cell differentiation |
| Ⅰ-10-3 |
Cell-to-cell interaction |
| Ⅰ-10-4 |
Cell culture system/Organoid |
| Ⅰ-10-5 |
Extracellular vesicles/Exosome |
| Ⅰ-10-6 |
Metabolism/Metabolome |
| Ⅰ-10-7 |
Carbohydrate chains and glycosyltransferases |
| Ⅰ-10-8 |
Telomere/
Aging/Senescence/
Immortalization |
| Ⅰ-10-9 |
Cell death |
| Ⅰ-10-10 |
Others |
11.Cancer immunity
| Ⅰ-11-1 |
Tumor antigens |
| Ⅰ-11-2 |
Antitumor immune response |
| Ⅰ-11-3 |
Tumor immune microenvironment/Tumor immune escape |
| Ⅰ-11-4 |
Immune checkpoint inhibitors |
| Ⅰ-11-5 |
Antibody therapy |
| Ⅰ-11-6 |
Immune cell therapy (CAR-T, T cell therapy) |
| Ⅰ-11-7 |
Cancer vaccines |
| Ⅰ-11-8 |
Other immunotherapies |
| Ⅰ-11-9 |
Others |
12.Diagnosis
| Ⅰ-12-1 |
Pathological diagnosis |
| Ⅰ-12-2 |
Pathological analysis |
| Ⅰ-12-3 |
Diagnostic imaging/Cancer imaging |
| Ⅰ-12-4 |
Diagnosis by tumor markers and biomarkers |
| Ⅰ-12-5 |
Genomic diagnostics/Panel sequencing |
| Ⅰ-12-6 |
Diagnosis by expression analysis (mRNA, protein) |
| Ⅰ-12-7 |
Liquid biopsy |
| Ⅰ-12-8 |
Artificial intelligence based diagnostics |
| Ⅰ-12-9 |
Others |
13.Molecular-targeted therapy
| Ⅰ-13-1 |
Signal transduction inhibitors/Kinase inhibitors |
| Ⅰ-13-2 |
Angiogenesis inhibitors/Antimetastatic drugs |
| Ⅰ-13-3 |
Epigenetic drugs |
| Ⅰ-13-4 |
Proteolysis (proteasome inhibitors/PROTAC) |
| Ⅰ-13-5 |
Engineered antibodies (ADC etc.) |
| Ⅰ-13-6 |
Sensitivity and resistance to molecularly targeted drugs |
| Ⅰ-13-7 |
Others |
14.Chemotherapy/Endocrine therapy
| Ⅰ-14-1 |
Natural anticancer compounds |
| Ⅰ-14-2 |
Synthetic anticancer compounds |
| Ⅰ-14-3 |
DNA-damaging drugs (Platinum compounds/Topoisomerase inhibitors etc.) |
| Ⅰ-14-4 |
Antimicrotubule drugs (Taxanes/Alkaloids etc.) |
| Ⅰ-14-5 |
Anticancer drug sensitivity/Drug resistance |
| Ⅰ-14-6 |
Anticancer drug and cell death |
| Ⅰ-14-7 |
Drug delivery system |
| Ⅰ-14-8 |
Combinational therapy/Adjuvant therapy |
| Ⅰ-14-9 |
Endocrine therapy |
| Ⅰ-14-10 |
Others |
15.Evaluation and prediction of pharmacological effects
| Ⅰ-15-1 |
Pharmacokinetics/Pharmacodynamics |
| Ⅰ-15-2 |
Sensitivity test |
| Ⅰ-15-3 |
Clinical trial/Translational research |
| Ⅰ-15-4 |
Others |
16.Radiation therapy
| Ⅰ-16-1 |
Radiation and particle therapy |
| Ⅰ-16-2 |
Radiosensitivity/Efficacy enhancement |
| Ⅰ-16-3 |
RI therapy |
| Ⅰ-16-4 |
Others |
17.Surgical therapy
| Ⅰ-17-1 |
Surgical intervention |
| Ⅰ-17-2 |
Multimodal treatment in surgery |
| Ⅰ-17-3 |
Others |
18.Cell therapy/Gene therapy
| Ⅰ-18-1 |
Stem cells |
| Ⅰ-18-2 |
Generation and modification of vectors |
| Ⅰ-18-3 |
Designer cells |
| Ⅰ-18-4 |
Others |
19.Cancer prevention / Epidemiology
| Ⅰ-19-1 |
Synthetic compounds |
| Ⅰ-19-2 |
Natural products |
| Ⅰ-19-3 |
Dietary/alimentary factors |
| Ⅰ-19-4 |
Environmental factors (life habits etc.)/Infectious exposure |
| Ⅰ-19-5 |
Cancer-prone syndromes/Molecular epidemiology |
| Ⅰ-19-6 |
Cohort study/Descriptive epidemiology/Cancer registration |
| Ⅰ-19-7 |
Others |
20.Information/informatics
| Ⅰ-20-1 |
Bioinformatics |
| Ⅰ-20-2 |
Big data analysis/Real world evidence |
| Ⅰ-20-3 |
Management and analysis of cancer patients' data |
| Ⅰ-20-4 |
Mathmatical modeling and simulation |
| Ⅰ-20-5 |
Others |
21.Advanced cancer care/Cancer and society
| Ⅰ-21-1 |
Palliative Medicine |
| Ⅰ-21-2 |
Social cancer control action |
| Ⅰ-21-3 |
Others |
Category II (Specific tumors)
1.Specific Tumors
| Ⅱ-1-1 |
Brain tumors |
| Ⅱ-1-2 |
Gastrointestinal tumors |
| Ⅱ-1-3 |
Hepatobiliary and pancreatic tumors |
| Ⅱ-1-4 |
Head and neck tumors/Thyroid tumors |
| Ⅱ-1-5 |
Lung cancer/Thoracic tumors |
| Ⅱ-1-6 |
Breast cancer |
| Ⅱ-1-7 |
Gynecologic tumors |
| Ⅱ-1-8 |
Bone and soft tissue tumors |
| Ⅱ-1-9 |
Urological tumors |
| Ⅱ-1-10 |
Skin tumors |
| Ⅱ-1-11 |
Hematological malignancies |
| Ⅱ-1-12 |
Pediatric tumors/AYA-generation tumors |
| Ⅱ-1-13 |
Rare cancer/Carcinoma of Unknown Primary |
| Ⅱ-1-14 |
Tumor-agnostic approach |
| Ⅱ-1-15 |
Others |
